American Association of Individual Investors3d
Why BioMarin Pharmaceutical Inc.’s (BMRN) Stock Is Down 10.70%
BioMarin Pharmaceutical Inc.’s BMRN share price has dipped by 10.70%, which has investors questioning if this is right time ...
BioMarin Pharmaceutical: Pegasus Success May Lead To Palynziq Label Expansion
BioMarin Pharmaceutical Inc. has advancements in phenylketonuria treatment. Click to learn how Palynziq's success could ...
RBC Capital Sticks to Their Hold Rating for BioMarin Pharmaceutical (BMRN)
RBC Capital analyst Luca Issi maintained a Hold rating on BioMarin Pharmaceutical (BMRN – Research Report) on April 3 and set a price target of ...
Clinical Trials Arena on MSN3d
BioMarin’s trial for phenylketonuria therapy meets primary efficacy endpoint
BioMarin Pharmaceutical has reported that the multi-centre Phase III PEGASUS trial of Palynziq (pegvaliase-pqpz) has met its ...
Is BioMarin Pharmaceutical Inc. (BMRN) The Most Profitable Biotech Stock To Buy Right Now?
We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a ...
2 Reasons to Like BMRN (and 1 Not So Much)
Stocks We Like Even More Than BioMarin Pharmaceutical The Trump trade may have passed, but rates are still dropping and ...
Pharmabiz3d
BioMarin Pharma’s phase 3 PEGASUS trial evaluating Palynziq in adolescents with phenylketonuria meets primary efficacy endpoint
San Rafael, California Thursday, April 3, 2025, 18:00 Hrs [IST] ...
BioMarin Seeks Label Expansion For Palynziq After Positive Phase 3 Results In Adolescent Patients
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released topline data from the Phase 3 PEGASUS trial evaluating Palynziq ...
Truist Financial Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)
In a report released today, Joon Lee from Truist Financial maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report). The ...
BioMarin Announces Positive Pivotal Data for PALYNZIQ® (pegvaliase-pqpz) in Adolescents with Phenylketonuria
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Phase 3 PEGASUS trial evaluating PALYNZIQ® (pegvaliase-pqpz) met its primary efficacy endpoint, demonstrating a statistically ...
The Pharma Letter3d
Positive pivotal data for Palynziq in adolescents
US biotech BioMarin Pharmaceutical (Nasdaq: BMRN) yesterday revealed that the Phase III PEGASUS trial evaluating Palynziq (pegvaliase-pqpz) met its primary efficacy endpoint, demonstrating a ...